The Safety and Immunogenicity of GTU®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART

Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV

(2018) Youry Kim et al.   Cell Host & Microbe

Therapeutic vaccination for HIV

(2018) Kathryn E. Stephenson   Current Opinion in HIV and AIDS

Barriers for HIV Cure: The Latent Reservoir

(2018) Sergio Castro-Gonzalez et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

(2018) Sharon A Riddler et al.   Open Forum Infectious Diseases

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects

(2017) Gemma Hancock et al.   Journal of the International AIDS Society

Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial

(2017) G. Haidari et al.   Scientific Reports

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

(2016)   AIDS

The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

(2016) Jeffrey M. Jacobson et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

CD8+T Cell Breadth andEx VivoVirus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles

(2016) Catherine K. Koofhethile et al.   JOURNAL OF VIROLOGY

Therapeutic vaccines and immunological intervention in HIV infection

(2016) Giuseppe Pantaleo et al.   Current Opinion in HIV and AIDS

DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus

(2016) Melanie Thompson et al.   PLoS One

Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV

(2014) Pablo Tebas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

(2013) Hasina Samji et al.   PLoS One

Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU®-Multi-HIVB, in untreated HIV-1 infected subjects

(2012) Eftyhia Vardas et al.   VACCINE

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers

(2011) Sandhya Vasan et al.   PLoS One

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates

(2010) Aggeliki Spentzou et al.   JOURNAL OF INFECTIOUS DISEASES

Preferential Amplification of CD8 Effector-T Cells after Transcutaneous Application of an Inactivated Influenza Vaccine: A Randomized Phase I Trial

(2010) Behazine Combadière et al.   PLoS One

The role of IFN-γ Elispot assay in HIV vaccine research

(2009) Hendrik Streeck et al.   Nature Protocols